MIM
MCRB icon

MetLife Investment Management’s Seres Therapeutics MCRB Stock Holding History

MetLife Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,572
Closed -$122K – 2851
2023
Q3 		$122K Hold
2,572
– – ﹤0.01% 2476
2023
Q2 		$246K Buy
2,572
+691
+37% +$75.2K ﹤0.01% 2147
2023
Q1 		$213K Buy
1,881
+284
+18% +$30.7K ﹤0.01% 2184
2022
Q4 		$179K Sell
1,597
-332
-17% -$44.5K ﹤0.01% 2317
2022
Q3 		$248K Buy
1,929
+1,338
+226% +$137K ﹤0.01% 2148
2022
Q2 		$40.6K Sell
591
-1,396
-70% -$120K ﹤0.01% 2816
2022
Q1 		$283K Buy
1,987
+710
+56% +$109K ﹤0.01% 2127
2021
Q4 		$213K Buy
1,277
+634
+99% +$101K ﹤0.01% 2018
2021
Q3 		$89.5K Sell
643
-630
-49% -$123K ﹤0.01% 2483
2021
Q2 		$607K Buy
1,273
+191
+18% +$80.6K 0.01% 1454
2021
Q1 		$446K Sell
1,082
-57
-5% -$26.2K ﹤0.01% 1594
2020
Q4 		$558K Hold
1,139
– – 0.01% 1433
2020
Q3 		$645K Sell
1,139
-1
-0.1% -$333 0.01% 1240
2020
Q2 		$109K Buy
+1,140
New +$100K ﹤0.01% 2218

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's MCRB Position: Q4 2023 in Review

MetLife Investment Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 2,572 shares — an estimated $122K sold.

MetLife Investment Management first reported a position in MCRB in Q2 2020 and held it in 14 quarters. The position peaked at $645K in Q3 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • MetLife Investment Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • MetLife Investment Management sold 2,572 Seres Therapeutics shares in Q4 2023, an estimated $122K.
  • MetLife Investment Management first reported a position in Seres Therapeutics in Q2 2020 and held it in 14 quarters.
  • MetLife Investment Management's Seres Therapeutics position peaked at $645K in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.